Skip to main content
The FDA has approved a potassium channel blocker to improve walking in adults with multiple sclerosis.

Dalfampridine Extended Release Tables (Ampyra™ )

The FDA has approved a potassium channel blocker to improve walking in adults with multiple sclerosis.